NCT03440437 2025-07-01
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
invoX Pharma Limited
Phase 1/2 Terminated
invoX Pharma Limited
Ohio State University Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
Radiation Therapy Oncology Group